文献速递治疗药物监测与药物基因组学特殊人群用药

肾移植后妊娠期他克莫司药代动力学变化模型:回顾性队列研究

Modelling changes in the pharmacokinetics of tacrolimus during pregnancy after kidney transplantation: A retrospective cohort study.
PubMed 文献 · Br J Clin Pharmacol · 2023-09-04

该回顾性队列研究纳入14例肾移植后妊娠女性,收集260份全血他克莫司谷浓度,采用非线性混合效应模型分析药代动力学。结果显示妊娠期他克莫司清除率从34.5 L/h升至41.7 L/h,较孕前分别增加15%、19%和21%(第一、二、三孕期),红细胞压积和孕龄可解释部分个体间及个体内变异。

要点

  • 妊娠期他克莫司清除率增加,需按相同比例增加剂量以维持孕前目标谷浓度。
  • 红细胞压积和孕龄与他克莫司清除率负相关(P ≤ 0.01)。
  • 该模型可解释18%个体间和85%个体内口服清除率变异。

核心结论

  • 妊娠期他克莫司清除率增加导致暴露降低,需增加剂量以维持孕前目标全血谷浓度。

研究设计与样本

  • 回顾性队列研究,纳入14例肾移植后妊娠女性,收集孕前6个月至产后6个月共260份全血他克莫司谷浓度,采用非线性混合效应模型进行群体药代动力学分析。

主要发现

  • 他克莫司清除率从孕前34.5 L/h升至妊娠期41.7 L/h,第一、二、三孕期分别较孕前增加15%、19%和21%。
  • 红细胞压积和孕龄与他克莫司清除率呈负相关(P ≤ 0.01),共解释18%个体间和85%个体内口服清除率变异。

关键数值与推荐

  • 为维持孕前目标全血他克莫司谷浓度,妊娠期需按清除率增加百分比(第一孕期15%、第二孕期19%、第三孕期21%)相应增加剂量。

临床怎么用

  • 临床应密切监测妊娠期他克莫司全血谷浓度,根据孕龄和红细胞压积变化及时调整剂量以维持孕前目标浓度。

局限性

  • 回顾性研究,样本量较小(14例妊娠女性,260份浓度),需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Pregnancy after kidney transplantation is realistic but immunosuppressants should be continued to prevent rejection. Tacrolimus is safe during pregnancy and is routinely dosed based on whole-blood predose concentrations. However, maintaining these concentrations is complicated as physiological changes during pregnancy affect tacrolimus pharmacokinetics. The aim of this study was to describe tacrolimus pharmacokinetics throughout pregnancy and explain the changes by investigating covariates in a population pharmacokinetic model. METHODS: Data of pregnant women using a twice-daily tacrolimus formulation following kidney transplantation were retrospectively collected from 6 months before conception, throughout gestation and up to 6 months postpartum. Pharmacokinetic analysis was performed using nonlinear mixed effects modelling. Demographic, clinical and genetic parameters were evaluated as covariates. The final model was evaluated using goodness-of-fit plots, visual predictive checks and a bootstrap analysis. RESULTS: A total of 260 whole-blood tacrolimus predose concentrations from 14 pregnant kidney transplant recipients were included. Clearance increased during pregnancy from 34.5 to 41.7 L/h, by 15, 19 and 21% in the first, second and third trimester, respectively, compared to prior to pregnancy. This indicates a required increase in the tacrolimus dose by the same percentage to maintain the prepregnancy concentration. Haematocrit and gestational age were negatively correlated with tacrolimus clearance (P ≤ 0.01), explaining 18% of interindividual and 85% of interoccasion variability in oral clearance. CONCLUSIONS: Tacrolimus clearance increases during pregnancy, resulting in decreased exposure to tacrolimus, which is explained by gestational age and haematocrit. To maintain prepregnancy target whole-blood tacrolimus predose concentrations during pregnancy, increasing the dose is required.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Schagen MR, Ulu AN, Francke MI, et al. Modelling changes in the pharmacokinetics of tacrolimus during pregnancy after kidney transplantation: A retrospective cohort study. Br J Clin Pharmacol. 2023. PMID: 37596793. doi:10.1111/bcp.15886

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。